These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35405339)

  • 41. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world.
    Prasad M; Lambe UP; Brar B; Shah I; J M; Ranjan K; Rao R; Kumar S; Mahant S; Khurana SK; Iqbal HMN; Dhama K; Misri J; Prasad G
    Biomed Pharmacother; 2018 Jan; 97():1521-1537. PubMed ID: 29793315
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches.
    Wang W; Huang Z; Huang Y; Zhang X; Huang J; Cui Y; Yue X; Ma C; Fu F; Wang W; Wu C; Pan X
    Adv Drug Deliv Rev; 2022 Jun; 185():114309. PubMed ID: 35469997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current landscape of treating different cancers using nanomedicines: Trends and perspectives.
    Morales CS; Grodzinski P
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(1):e1927. PubMed ID: 37706362
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strategies targeting tumor immune and stromal microenvironment and their clinical relevance.
    Hu M; Huang L
    Adv Drug Deliv Rev; 2022 Apr; 183():114137. PubMed ID: 35143893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug delivery to macrophages: a review of nano-therapeutics targeted approach for inflammatory disorders and cancer.
    Mukhtar M; Ali H; Ahmed N; Munir R; Talib S; Khan AS; Ambrus R
    Expert Opin Drug Deliv; 2020 Sep; 17(9):1239-1257. PubMed ID: 32543950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances on transdermal delivery systems for the treatment of arthritic injuries: From classical treatment to nanomedicines.
    Shang H; Younas A; Zhang N
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 May; 14(3):e1778. PubMed ID: 35112483
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dual-receptor-targeted nanomedicines: emerging trends and advances in lung cancer therapeutics.
    Vikas ; Sahu HK; Mehata AK; Viswanadh MK; Priya V; Muthu MS
    Nanomedicine (Lond); 2022 Aug; 17(19):1375-1395. PubMed ID: 36317852
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy.
    Raj S; Khurana S; Choudhari R; Kesari KK; Kamal MA; Garg N; Ruokolainen J; Das BC; Kumar D
    Semin Cancer Biol; 2021 Feb; 69():166-177. PubMed ID: 31715247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
    Kwon S; Ko H; You DG; Kataoka K; Park JH
    Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Minimally invasive nanomedicine: nanotechnology in photo-/ultrasound-/radiation-/magnetism-mediated therapy and imaging.
    Ouyang J; Xie A; Zhou J; Liu R; Wang L; Liu H; Kong N; Tao W
    Chem Soc Rev; 2022 Jun; 51(12):4996-5041. PubMed ID: 35616098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Where Is Nano Today and Where Is It Headed? A Review of Nanomedicine and the Dilemma of Nanotoxicology.
    Domingues C; Santos A; Alvarez-Lorenzo C; Concheiro A; Jarak I; Veiga F; Barbosa I; Dourado M; Figueiras A
    ACS Nano; 2022 Jul; 16(7):9994-10041. PubMed ID: 35729778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protein corona: challenges and opportunities for targeted delivery of nanomedicines.
    Jiang Z; Chu Y; Zhan C
    Expert Opin Drug Deliv; 2022 Jul; 19(7):833-846. PubMed ID: 35738018
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peptide-decorated polymeric nanomedicines for precision cancer therapy.
    Sun H; Dong Y; Feijen J; Zhong Z
    J Control Release; 2018 Nov; 290():11-27. PubMed ID: 30290243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
    Wang Y; Cai R; Chen C
    Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer nanomedicines: so many papers and so few drugs!
    Venditto VJ; Szoka FC
    Adv Drug Deliv Rev; 2013 Jan; 65(1):80-8. PubMed ID: 23036224
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Development of Drug Delivery Technology and Nanomedicine by Using Gold Nanoparticles].
    Ozeki T; Tagami T
    Yakugaku Zasshi; 2021; 141(3):323-326. PubMed ID: 33642498
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
    Halwani AA
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
    He Q; Shi J
    Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.
    Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M
    Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New challenges in the use of nanomedicine in cancer therapy.
    Rasool M; Malik A; Waquar S; Arooj M; Zahid S; Asif M; Shaheen S; Hussain A; Ullah H; Gan SH
    Bioengineered; 2022 Jan; 13(1):759-773. PubMed ID: 34856849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.